clinical trial · NCT06095388
Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA
JCR Pharmaceuticals Co., Ltd.·phase2·active not recruiting·n = 15
Mucopolysaccharidosis III-AJR-441JR-441JR-441
brief summary
A Phase I/ II, open-label, randomized, 2-arm study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.
started
Oct 4, 2023
primary completion
Oct 31, 2029
completion
Oct 31, 2029
last updated
Aug 26, 2025
official title
Phase I/II Study of Weekly Infusions of JR-441 in Patients With Mucopolysaccharidosis Type IIIA
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol